Associated Papers
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
Different Contribution of Missense and Loss-of-Function Variants to the Genetic Structure of Familial and Sporadic Meniere Disease.
Parra-Perez AM et al.
Medcomm, 2025
Clinical and functional evidence for the pathogenicity of the LRRK2 p.Arg1067Gln variant.
Lim SY et al.
Npj Parkinson's Disease, 2025
NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations.
Bandres-Ciga S et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Gene Panel Sequencing Analysis Revealed a Strong Contribution of Rare Coding Variants to the Risk of Parkinson's Disease in Sporadic Moroccan Patients.
Smaili I et al.
Journal of Molecular Neuroscience : Mn, 2023
Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.
Thakur G et al.
Genes, 2022
Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease.
Smith LJ et al.
Frontiers in Neurology, 2022
Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings.
Guadagnolo D et al.
Frontiers in Neurology, 2021
Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression.
Lau E et al.
Genome Medicine, 2020
Targeted next-generation sequencing identifies novel variants in candidate genes for Parkinson's disease in Black South African and Nigerian patients.
Oluwole OG et al.
Bmc Medical Genetics, 2020
LRRK2 in Parkinson disease: challenges of clinical trials.
Tolosa E et al.
Nature Reviews. Neurology, 2020
LRRK2 Phosphorylation, More Than an Epiphenomenon.
Marchand A et al.
Frontiers in Neuroscience, 2020
A genetic analysis of a Spanish population with early onset Parkinson's disease.
Cristina TP et al.
Plos One, 2020
Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
Zhao Y et al.
Drugs, 2019
A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.
Melloni GEM et al.
Breast Cancer Research : Bcr, 2017
Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.
Melachroinou K et al.
Plos One, 2016
Evaluating LRRK2 genetic variants with unclear pathogenicity.
Refai FS et al.
Biomed Research International, 2015
Genetic assessment of familial and early-onset Parkinson's disease in a Greek population.
Bozi M et al.
European Journal of Neurology, 2014
Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe.
Rubio JP et al.
Human Mutation, 2012
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA et al.
The Lancet. Neurology, 2011
Genetic analysis of LRRK2 functional domains in Brazilian patients with Parkinson's disease.
Abdalla-Carvalho CB et al.
European Journal of Neurology, 2010
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.
Nuytemans K et al.
Human Mutation, 2010
Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease.
Lesage S et al.
Journal of Medical Genetics, 2009